Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Ingo V. Hartung"'
Autor:
Lilia Falkenstern, Victoria Georgi, Stefanie Bunse, Volker Badock, Manfred Husemann, Ulrike Roehn, Timo Stellfeld, Mark Fitzgerald, Steven Ferrara, Detlef Stöckigt, Carlo Stresemann, Ingo V. Hartung, Amaury Fernández-Montalván
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-21 (2024)
Abstract The market approval of Tazemetostat (TAZVERIK) for the treatment of follicular lymphoma and epithelioid sarcoma has established “enhancer of zeste homolog 2” (EZH2) as therapeutic target in oncology. Despite their structural similarities
Externí odkaz:
https://doaj.org/article/86f7032f806147479748eda7c74b8341
Autor:
Frank Wunder, Johannes‐Peter Stasch, Andreas Knorr, Thomas Mondritzki, Damian Brockschnieder, Eva‐Maria Becker‐Pelster, Peter Sandner, Hanna Tinel, Gorden Redlich, Ingo V. Hartung, Alexandros Vakalopoulos, Markus Follmann
Publikováno v:
British Journal of Pharmacology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a228384b0e7a00316193cfbba4881cf9
https://doi.org/10.1111/bph.16142
https://doi.org/10.1111/bph.16142
Autor:
Alexandros Vakalopoulos, Frank Wunder, Ingo V. Hartung, Gorden Redlich, Rolf Jautelat, Philipp Buchgraber, Jorma Hassfeld, Alexey V. Gromov, Niels Lindner, Donald Bierer, Jörg Gries, Walter Kroh, Holger Paulsen, Joachim Mittendorf, Dieter Lang, Eva Becker-Pelster, Damian Brockschnieder, Volker Geiss, Volkhart Li, Alexander Straub, Andreas Knorr, Thomas Mondritzki, Hubert Trübel, Marian Raschke, Martina Schaefer, Dirk Thomas, Peter Sandner, Johannes-Peter Stasch, Markus Follmann
Publikováno v:
Journal of Medicinal Chemistry.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73f98e7d872f77068d8ae9eeaa915fa4
https://doi.org/10.1021/acs.jmedchem.2c02082
https://doi.org/10.1021/acs.jmedchem.2c02082
Autor:
Johannes Krieger, Fiona J. Sorrell, Ansgar A. Wegener, Birgitta Leuthner, Fouzia Machrouhi‐Porcher, Martin Hecht, Eva M. Leibrock, Juliane E. Müller, Jonathan Eisert, Ingo V. Hartung, Sarah Schlesiger
Publikováno v:
ChemMedChem. 18
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74e6925de7e93dcced38b905feb622af
https://doi.org/10.1002/cmdc.202200615
https://doi.org/10.1002/cmdc.202200615
Autor:
Jean Quancard, Anna Vulpetti, Anders Bach, Brian Cox, Stéphanie M. Guéret, Ingo V. Hartung, Hannes F. Koolman, Stefan Laufer, Josef Messinger, Gianluca Sbardella, Russell Craft
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::514e82a2fe9693d245f09a5e32cb9327
https://hdl.handle.net/11386/4818531
https://hdl.handle.net/11386/4818531
Autor:
Suzanne Ackloo, Albert A. Antolin, Jose Manuel Bartolome, Hartmut Beck, Alex Bullock, Ulrich A. K. Betz, Jark Böttcher, Peter J. Brown, Menorca Chaturvedi, Alisa Crisp, Danette Daniels, Jan Dreher, Kristina Edfeldt, Aled M. Edwards, Ursula Egner, Jon Elkins, Christian Fischer, Tine Glendorf, Steven Goldberg, Ingo V. Hartung, Alexander Hillisch, Evert Homan, Stefan Knapp, Markus Köster, Oliver Krämer, Josep Llaveria, Uta Lessel, Sven Lindemann, Lars Linderoth, Hisanori Matsui, Maurice Michel, Florian Montel, Anke Mueller-Fahrnow, Susanne Müller, Dafydd R. Owen, Kumar Singh Saikatendu, Vijayaratnam Santhakumar, Wendy Sanderson, Cora Scholten, Matthieu Schapira, Sujata Sharma, Brock Shireman, Michael Sundström, Matthew H. Todd, Claudia Tredup, Jennifer Venable, Timothy M. Willson, Cheryl H. Arrowsmith
Publikováno v:
RSC Medicinal Chemistry.
Target 2035, an international federation of biomedical scientists from the public and private sectors, is leveraging ‘open’ principles to develop a pharmacological tool for every human protein.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3307d439e596fca276308b7255fe64f6
https://doi.org/10.1039/d2md00441k
https://doi.org/10.1039/d2md00441k
Autor:
Susanne Müller, Suzanne Ackloo, Cheryl H Arrowsmith, Marcus Bauser, Jeremy L Baryza, Julian Blagg, Jark Böttcher, Chas Bountra, Peter J Brown, Mark E Bunnage, Adrian J Carter, David Damerell, Volker Dötsch, David H Drewry, Aled M Edwards, James Edwards, Jon M Elkins, Christian Fischer, Stephen V Frye, Andreas Gollner, Charles E Grimshaw, Adriaan IJzerman, Thomas Hanke, Ingo V Hartung, Steve Hitchcock, Trevor Howe, Terry V Hughes, Stefan Laufer, Volkhart MJ Li, Spiros Liras, Brian D Marsden, Hisanori Matsui, John Mathias, Ronan C O'Hagan, Dafydd R Owen, Vineet Pande, Daniel Rauh, Saul H Rosenberg, Bryan L Roth, Natalie S Schneider, Cora Scholten, Kumar Singh Saikatendu, Anton Simeonov, Masayuki Takizawa, Chris Tse, Paul R Thompson, Daniel K Treiber, Amélia YI Viana, Carrow I Wells, Timothy M Willson, William J Zuercher, Stefan Knapp, Anke Mueller-Fahrnow
Publikováno v:
eLife, Vol 7 (2018)
Potent, selective and broadly characterized small molecule modulators of protein function (chemical probes) are powerful research reagents. The pharmaceutical industry has generated many high-quality chemical probes and several of these have been mad
Externí odkaz:
https://doaj.org/article/959198e7fd31440495c0d4c7cf3c5c06
Publikováno v:
Nature Reviews Chemistry. 7:3-4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ff183f1285649bc8a8e6a4c1c8b731e
https://doi.org/10.1038/s41570-022-00451-0
https://doi.org/10.1038/s41570-022-00451-0
Autor:
Roland Neuhaus, Ingo V. Hartung, G. Siemeister, Marion Hitchcock, Arne Scholz, Stefanie Hammer, Dominic Brittain, Kirstin Petersen, Roman C. Hillig, Florian Pühler
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 23:2384-2390
Using PD325901 as a starting point for identifying novel allosteric MEK inhibitors with high cell potency and long-lasting target inhibition in vivo, truncation of its hydroxamic ester headgroup was combined with incorporation of alkyl and aryl ether
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::906a87ca708db061bad0c419e3d20d92
https://doi.org/10.1016/j.bmcl.2013.02.028
https://doi.org/10.1016/j.bmcl.2013.02.028
Autor:
Florian Pühler, Arne Scholz, Roman C. Hillig, Ingo V. Hartung, Marion Hitchcock, G. Siemeister, Rolf Bohlmann, Stefanie Hammer, Roland Neuhaus
Publikováno v:
Bioorganicmedicinal chemistry letters. 26(1)
Recently, we had identified an unexplored pocket adjacent to the known binding site of allosteric MEK inhibitors which allowed us to design highly potent and in vivo efficacious novel inhibitors. We now report that our initial preclinical candidate,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86a653eef4df0b4c841fd02a76b7baaa
https://pubmed.ncbi.nlm.nih.gov/26611920
https://pubmed.ncbi.nlm.nih.gov/26611920